Thursday, October 4, 2018: 2:00 PM-3:15 PM
Room: N Hall D
At the conclusion of this session, participants will be able to:
- review novel antibiotics in the pipeline including mechanism of action and clinical applications
- discuss the possible niche of novel therapies against antibiotic-resistant organisms
- evaluate clinical and price-clinic data of new antimicrobial molecules that are being developed.
Academicians, Clinicians, Epidemiologists, Fellows, Healthcare workers, Hospital administrators, Hospital epidemiologists, Infection preventionists, Infectious diseases pediatricians, Infectious diseases physicians, Investigators, Medical students and residents, Members-in-training, Microbiologists, Nurses, Pharmacists, Researchers, Scientists
Trainee, Global ID, Investigative ID, Pediatric ID, Adult ID
David R. Andes, M.D., FIDSA, University of Wisconsin
Cesar Arias, MD, PhD, FIDSA, University of Texas Health Science Center at Houston
Robert Bonomo, MD, Louis Stokes Cleveland VA Medical Center
John Mohr, PharmD, Medical Affairs Strategic Solution, LLC
No CME credit is offered for this session.
D. R. Andes,
Merck & Co., Inc.: